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Abstract
Background: Elevated Plexin-B1 expression has been found in diverse human cancers and in non-neoplastic
tissues, and it mediates diverse biological and pathological activities. However, whether or not Plexin-B1 expression
is involved in human ovarian tumors remains unclear. In the present study, Plexin-B1 expression was explored in
benign and malignant human ovarian tumor tissues. In addition, the impact of Plexin-B1 expression on ovarian
cancer cell proliferation, migration and invasion were investigated in vitro.
Methods: Plexin-B1 expression was analyzed in normal and benign ovarian tissues and serous ovarian tumors
(both borderline and malignant) by immunohistochemical staining, as well as in four human ovarian cancer cell
lines (A2780, C13*, SKOV3, and OV2008) by RT-PCR and western blot analyses. Furthermore, endogenous Plexin-B1
expression was suppressed by Plexin-B1 siRNA in SKOV3 cells, which overexpress Plexin-B1. Protein levels of
Plexin-B1, AKT and AKT
Ser473 were examined by western blot analysis. Cell proliferation, migration and invasion
were measured with MTT, wound healing and boyden chamber assays, respectively, and the cytoskeleton was
monitored via F-actin staining.
Results: Expression levels of Plexin-B1 protein were significantly higher in serous ovarian carcinomas than in
normal ovaries or benign ovarian neoplasms, and in the former, Plexin-B1 expression was positively correlated with
lymphatic metastasis, and the membrane and cytoplasm of cancer cells stained positively. SKOV3 cells displayed
the highest Plexin-B1 expression at both the mRNA and protein levels among the four tested human ovarian
cancer cell lines and was selected as a cell model for further in vitro experiments. Plexin-B1 siRNA significantly
suppressed phosphorylation of AKT at Ser473 in SKOV3 cells, but it did not alter total AKT expression. In addition,
silencing of Plexin-B1 in SKOV3 cells inhibited cell migration and invasion and reorganized the cytoskeleton,
whereas cell proliferation was not affected.
Conclusion: Plexin-B1 expression correlates with malignant phenotypes of serous ovarian tumors, probably via
phosphorylation of AKT at Ser473, suggesting that Plexin-B1 might be a useful biomarker and/or a novel
therapeutic target.
Background
Plexin proteins comprise a large family of trans-mem-
brane receptors for semaphorins, which are secreted,
membrane-associated or GPI-anchored proteins origin-
ally identified for their role in axon guidance repulsion
[1]. In vertebrates, nine plexins are divided into four
subfamilies according to their different structures: plex-
inA1-4, plexinB1-3, plexin-C1 and plexin-D1 [1]. All the
plexins share significant homology in their extracellular
region with the scatter factor receptors c-Met and RON,
whereas the highly conserved cytoplasmic region of
plexins fails to show homology with any other trans-
membrane receptor protein [2]. Plexin-A subgroup
members bind secreted class III semaphorins by asso-
ciating with neuropilin-1 and neuropilin-2, and plexin-B
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majority of semaphorins are not assigned to a specific
receptor [4]. To date, it is known that plexin-B1 binds
Sema 4D, plexin-B2 binds Sema 4C and plexin-B3 binds
Sema 5A [5].
Plexin-semaphorin interactions typically play impor-
tant roles in processes such as neuron extension, axon
growth guidance and the maintenance of established
neuronal pathways. Recent studies have further revealed
that plexins-semaphorins are also expressed outside the
nervous system and that their interactions are involved
in the regulation of immune responses [6-10], morpho-
genetic lung development [11], the cardiovascular sys-
tem [12-15], the skeleton [16-18], and tumor growth
and metastasis [19,20].
It is unique that Plexin-B1, a transmembrane receptor,
interacts directly with Rho family GTPases through a
cytoplasmic Rho GTPase binding domain (RBD) [21,22].
Rho GTPases play important roles in regulating the
actin cytoskeleton during developmental processes [23]
such as cell adhesion [24], cell migration, axon guidance,
cell cycle events and membrane transport [25], suggest-
ing potential involvement of Plexin-B1 in cancer pro-
gression and metastasis. Swiercz et al. recently reported
that Plexin-B1 activates or inactivates RhoA in the pre-
sence of ErbB-2 or Met, respectively, and leads to pro-
or anti-migration effects [26]. Furthermore, recent stu-
dies have shown that loss of Plexin-B1 expression in
breast cancer correlates closely with ER status and indi-
cates a more aggressive tumor phenotype [27]. In renal
cell carcinomas, Plexin-B1 was down-regulated and
growth of cancer cells was inhibited [28]. However,
overexpression of Plexin-B1 promoted invasiveness in
prostate cancer [29]. These different and even opposing
results reflect the fact that the exact biological function
of Plexin-B1 in tumorigenesis and cancer progression is
not yet clear.
In the present study, the expression levels of Plexin-B1
protein were found to be higher in serous ovarian carci-
nomas than in normal ovaries or benign ovarian
neoplasms. We then characterized the expression of
Plexin-B1 in several ovarian cancer cell lines, and
SKOV3 showed highest level of Plexin-B1. To examine
the role of Plexin-B1 in SKOV3 cells, Plexin-B1 was
knocked down by using three different siRNA duplexes.
The results showed that silencing of Plexin-B1 inhibited
migration and invasion in SKOV3 cells. Even though
Plexin-B1 has been previously reported to be involved in
mouse ovary follicular growth and development [4], and
it might be a marker predicting unfavorable outcome in
ovarian serous carcinomas [30], only a limited number
of studies have investigated the role of Plexin-B1 in
ovarian carcinogenesis.
Methods
Tissue specimens and cell lines
A collection of tissue specimens including 20 normal
and benign ovarian samples (the benign ovarian tissues
were histologically diagnosed as serous cystadenoma),
20 serous borderline ovarian tumors, and 80 serous
ovarian cystadenocarcinomas, were obtained from the
Department of Pathology of Tongji Hospital with Insti-
tutional Review Board approval. Histological type and
grade were diagnosed according to the World Health
Organization (WHO) criteria [31]. Staging was based on
TNM classification of the International Union Against
Cancer (UICC) [32]. The human epithelial ovarian ade-
nocarcinoma cell line SKOV3 was purchased from
American Type Culture Collection (ATCC, Manassas,
VA, USA). The A2780 human ovarian epithelial carci-
noma cell line was obtained from the European Collec-
tion of Cell Cultures (ECACC, Salisbury, UK). The
OV2008 and C13* ovarian cancer cell lines were gifts
from Dr. Rakesh Goel in the Ottawa Regional Cancer
Center, Ottawa, Canada. SKOV3 cells were cultured in
McCOY’s 5A containing 10% fetal bovine serum. The
other cell lines were cultured in RPMI1640 containing
10% fetal bovine serum. Cell cultures were maintained
in a humidified atmosphere containing 5% CO2 at 37°C,
and the growth medium was renewed every 2-3 days.
All culture medium and supplements were purchased
from Invitrogen, Carlsbad, CA, USA.
Immunohistochemistry
Immunohistochemistry was performed on formalin-fixed,
paraffin-embedded sections (5 μmt h i c k )a c c o r d i n gt o
standard procedures. Briefly, after dewaxing and rehydra-
tion, antigen retrieval was done with 0.01 M citrate buffer
at pH 6.0 for 15 min in a microwave oven. Then endogen-
ous peroxidase activity was inhibited by incubating sec-
tions with 0.3% hydrogen peroxide for 30 min at 37°C,
non-specific binding was blocked with normal goat serum
for 30 min at 37°C, and this was followed by incubating
the sections with mouse monoclonal anti-human Plexin-
B1 (Santa Cruz Biotechnology, sc-28372, 1:100 dilution) at
4°C overnight. The primary antibody was detected using
biotinylated anti-mouse IgG. The signal was amplified by
avidin-biotin complex formation and developed with dia-
minobenzidine followed by counterstaining with hematox-
ylin. Finally, the slides were dehydrated and mounted.
Plexin-B1 immunoreactivity was determined using the
well-standardized H-Score system (H=I×P ) [33]. I is the
staining intensity, which was evaluated according to the
following criteria: 0 (no staining), 1 (weak immunostain-
ing), 2 (moderate immunostaining), 3 (strong immunos-
taining), and P is the percentage of positively stained cells
in each sample. A sample with an H score ≥20 was
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[30]. Furthermore, invasive human ductal breast cancer
samples that had been confirmed as highly expressing
Plexin-B1 in our previous study [34] were used as positive
controls, and negative controls were carried out by incu-
bating with non-immune mouse immunoglobulin (IgG) in
place of the primary antibody. Three observers who were
unaware of the clinical data independently scored the sec-
tions. Discrepancies in the scoring process were reviewed,
and a consensus was ultimately reached.
RT-PCR
Total RNA was extracted from ovarian cancer cells
using Trizol Reagent (Invitrogen, Life Technologies, CA,
USA) following the manufacture’s protocol. cDNA was
synthesized from 2 μgo ft o t a lR N Au s i n gS u p e r s c r i p t
reverse transcriptase (Life Technologies, CA, USA). Pri-
mer sequences used for Plexin-B1 detection were as fol-
lows, sense:5’-GCAGTGTGTTATCCTTTAATGAAA-3’;
and antisense:5’-CCACTACAAACTGACCCCTC-3’,
producing 150-bp fragments. The housekeeping gene
glyceraldehyde phosphate dehydrogenase (GAPDH) was
used for normalization (sense: 5’-TGATGACATCAA-
GAAGGTGGTGAAG-3’; and antisense: 5’-TCCTT
GGAGGCCATGTGG GCCAT-3’, 240 bp product). The
amplification conditions were 95°C for 1 min followed
by 30 cycles of 94°C for 30 s, 58°C for 30 s, and 72°C
for 45 s with a 5 min 72°C extension. PCR products
were analyzed by 1.2% agarose gel electrophoresis with
ethidium bromide for UV light transilluminator
visualization.
Western blotting
Confluent cells were lysed in lysis buffer (20 mM Tris-
HCl, pH 7.5, 150 mM sodium chloride, 1 mM EDTA, 1
mM EGTA, 1% Triton, 2.5 mM sodium pyrophosphate, 1
mM h-glycerolphosphate, 1 mM sodium orthovanadate,
0.5 mM phenylmethylsulfonyl fluoride, and 1 mg/mL leu-
peptin). Protein lysates (200 μg/lane) were subjected to
8% polyacrylamide gel electrophoresis and transferred
onto nitrocellulose membrane. Non-specific binding sites
were blocked by incubating the nitrocellulose membrane
for 1 h at 37°C with 5% nonfat dried milk in Tris-buffered
saline containing 0.05% Tween-20 (TBST). Membranes
were incubated overnight at 4°C with primary antibodies,
then washed and incubated with horseradish peroxidase
conjugated secondary antibody (Cell Signaling Technol-
ogy, Danvers, MA). Bands were visualized using
enhanced chemiluminescence system (ECL, Pierce, USA).
siRNA preparation and cell transfection
Three different siRNA duplexes targeting Plexin-B1
sequences as well as a negative control siRNA were
commercially designed and synthesized by Invitrogen,
Carlsbad, CA, USA. The sequences were as follows:
Plexin-B1 siRNA1, sense: 5’-UCAAAUUGCUGGCUA-
CUGCAGGAGG-3’; and anti-sense: 5’-CCUCCUGCA-
GUAGCCAGCAAUUUGA-3’; Plexin-B1 siRNA2, sense:
5’-AACUCAGGCAAAGAGUCAGGUGCCU-3’;a n d
anti-sense: 5’- AGGCACCUGACUCUUUGCCUGA-
GUU-3’; Plexin-B1 siRNA3, sense: 5’- AAGGUAUACA-
GACAGAUGGACAUCC-3’;a n da n t i - s e n s e :5 ’-G G A
UGUCCAUCUGUCUGUAUACCUU-3’.N e g a t i v ec o n -
trol siRNA, sense: 5’-AGGAGAUAUUUCGAGGCUU-3’;
antisense: 5’-AAGCUCGAAAUAUCUCCU-3’.T h e
siRNA sequences were submitted to BLAST http://www.
ncbi.nlm.nih.gov/blast/ to ensure their specificity of
targeting.
SKOV3 cells (3 × 10
5) were plated in 6-well plates and
allowed to adhere for 24 h. 200 pmol siRNA and 5 μl
Lipofectamine™ 2000 (Invitrogen) per well were diluted
separately in serum-free Opti MEM (Invitrogen) for a
final volume of 250 μl, gently mixed, and incubated at
room temperature for 5 min. Then, the diluted siRNA
solution and the diluted Lipofectamine2000 were mixed
gently and incubated at room temperature for 20 min.
The cells were washed with serum-free McCOY’s5 A ,
and then the diluted siRNA/Lipofectamine2000 complex
was added into the 6-well plates containing 1500 μl
serum-free McCOY’s 5A for 5 h, after which the com-
plex was replaced with normal cell culture medium.
Semi-quantitative real-time RT-PCR
T o t a lR N Aw a si s o l a t e dw i t hT R I z o lR e a g e n t( I n v i t r o -
gen) from cells cultured in the absence or presence of
siRNA for 24 h. Real-time RT-PCR amplifications were
carried out using DNase I (Promega)-treated total RNA.
Reactions were performed in a Stratagene MX3000P
system using Real-time PCR Master Mix (TOYOBO,
Japan). Primer sequences for real-time PCR were as fol-
lows, Plexin-B1: sense, 5’-ATGTCACCTGCCAGCAG-
CAC-3’,a n t i s e n s e ,5 ’-CAGCACTGTCCACACGCAG A-
3’;1 8 S :s e n s e ,5 ’-AGTCCCTGCCCTTTGACACA-3’,
antisense, 5’-GATCCGAGGGCCTCACTAAAC-3’.T h e
reaction conditions were 95°C for 1 min followed by 40
cycles of 95°C for 15 s, 60°C for 15 s, and 72°C for 30 s.
The ΔCt method was used to obtain relative expression
values of Plexin-B1 as compared with 18S gene
amplification.
Cell proliferation assays
Cell proliferation was determined by 3-(4, 5-
dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide
(MTT) assay. Briefly, cells cultured in the absence or
presence of Plexin-B1 siRNA or negative control siRNA
for 24 h were seeded into a 96-well plate at a density of
5×1 0
3 per well. After being starved overnight in quies-
cent medium, the cells were cultured for 72 h with 10%
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Co.) was added to each well and incubated for 4 h at
37°C, which was followed by adding 100 μlD M S Oa n d
incubating at 37°C for an additional 20 min. Absorbance
was read at 570 nm on a microplate reader.
Wound-healing assay
Cells were seeded in individual wells of a 6-well culture
plate. Untransfected cells and cells exposed to Plexin-B1
siRNA or negative control siRNA for 5 h were cultured
in quiescent medium for 24 h. Then, a sterile 10-ul pip-
ette tip was used to longitudinally scratch a constant-dia-
meter stripe in the confluent monolayer. The medium
and cell debris were aspirated away and replaced with 2
ml of fresh serum-free medium. Photographs were taken
at 0 h, 24 h and 48 h after wounding (corresponding to
24 h, 48 h and 72 h post-transfection) by phase contrast
microscopy. For statistical analysis, three randomly
selected points along each wound were marked, and the
horizontal distance between the migrating cells and the
initial wound was measured at 24 h and 48 h. Values
were means ± SD from at least three-independent experi-
ments. Differences between siRNA-treated and blank
control data were determined by a Student’s t-test, where
P < 0.05 was considered significant.
Cell invasion assay
Cell invasion was assayed using Transwell chambers
(Costar, Cambridge, MA, USA) with 8-μm pore polycar-
bonate filters that were coated with Matrigel™ (BD Bios-
ciences, Franklin Lakes, NJ). Cells cultured in the
absence or presence of siRNA for 24 h were seeded into
the upper chambers in serum-free medium at a density
of 2.5 × 10
4 per well, and 500 μl of NIH3T3 conditioned
medium was placed in the lower chamber as a chemo-
attractant. After 48 h at 37°C in 5% CO2, the cells were
fixed with 3.7% paraformaldehyde and stained with 0.1%
crystal violet solution. Cells on the upper surface of the
filter were removed with cotton buds. Invaded cells on
the underside of the filter were photographed and
counted by phase contrast microscopy (×200 magnifica-
tions). The experiments were performed in triplicate.
Rhodamine phalloidin
SKOV3 cells were plated overnight on sterile glass cov-
erslips in a six-well plate 24 h after a 5-h exposure to
Plexin-B1 siRNA, negative control siRNA, or no treat-
ment. The cells were washed in PBS, fixed in 3.7% par-
aformaldehyde, permeabilized in 0.1% Triton-X100,
incubated in blocking solution (1% bovine serum albu-
min [BSA]), and then were kept for 20 min at room
temperature in rhodamine-phalloidin solution. Images
were acquired with a confocal laser scanning microscope
(The Olympus FluoView FV1000).
Statistical analysis
All experiments were repeated at least three times. The
software package SPSS13.5 was used to analyze data. P
< 0.05 was defined as statistically significant. All values
were presented as means ± standard deviation (SD).
Results
Expression of Plexin-B1 in human ovarian tissues with
different pathological changes
To elucidate the expression of Plexin-B1 protein during
serous ovarian carcinogenesis and to study the associa-
tion of Plexin-B1 expression with clinical-pathological
parameters, the expression levels of this protein in nor-
mal human ovaries, benign ovarian tissue, serous border-
line ovarian tumors and malignant ovarian tumors were
investigated with immunohistochemistry. As summarized
in Table 1, Plexin-B1 immunoreactivity was present in 3
(15.00%) normal and benign ovarian samples (Figure 1A,
1B), in 7 (35.00%) borderline tumors (Figure 1C) and in
44 (55.00%) cystadenocarcinomas. The expression of
Plexin-B1 in serous ovarian cystadenocarcinomas was
statistically higher than that in the normal and benign tis-
sues. In borderline tumors, the expression levels of
Plexin-B1 were neither significantly higher nor signifi-
cantly lower than the levels in the normal and benign tis-
sues or the cystadenocarcinomas. Furthermore, in
ovarian cystadenocarcinomas, the membrane and cyto-
plasm of the tumor cells was positive for Plexin-B1
immunostaining (Figure 1D), and a significant difference
(P = 0.008) in positive staining was observed between
samples with lymph node metastasis (75.00%) and those
without lymph node metastasis (44.23%). Although
Plexin-B1 immunoreactivity increased gradually from
stage I (45.00%) to stage IV (70.00%), there were no sta-
tistical differences. No correlation was found between
Plexin-B1 expression and age or cell differentiation.
Expression of Plexin-B1 in human ovarian cancer cell lines
To further investigate Plexin-B1 expression in ovarian
cancer cells, RT-PCR and western blot analysis were
used to detect Plexin-B1 mRNA and protein levels in
four human ovarian cancer cell lines: SKOV3, A2780,
C13* and OV2008. The results showed that Plexin-B1
expression levels were the highest in the SKOV3,
whereas faint Plexin-B1 expression was found in the
OV2008 cells (Figure 1E, F). Thus, SKOV3 cells were
selected as a model for further investigation.
Specific silencing of Plexin-B1 in SKOV3 cells with Plexin-
B1 siRNA
The experiments described in this study were performed
by transfection of SKOV3 cells with 200 pmol siRNA
for 24 h, which offered the best silencing efficiency in
our preliminary experiments.
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and a negative control siRNA were separately trans-
ferred into SKOV3 cells. At 24 h after transfection,
Plexin-B1 mRNA and protein levels were assessed by
real-time PCR and western blot analysis, respectively. As
shown in Figure 2A-C, each of the three Plexin-B1
siRNA duplexes significantly reduced the amount of
Plexin-B1 mRNA and protein. The data are from densi-
tometric analyses of Plexin-B1: b-actin; n = 5 indepen-
dent experiments.
Silencing of Plexin-B1 down-regulats phospho-AKT
(Ser473) expression in SKOV3 cells
Numerous studies showed that the PI3K/AKT pathway
is constitutively overexpressed in ovarian cancers [35]
and is involved in regulating malignant cellular
responses such as growth, survival, migration, and inva-
sion [36]. To investigate the relationship between
Plexin-B1 expression and PI3K/AKT signaling, we moni-
tored the effect of Plexin-B1 silencing on total AKT
level and its phosphorylation level in SKOV3 cells. As
s h o w ni nF i g u r e2 B ,C ,i n h i b i t i o no fP l e x i n - B 1
expression decreased the levels of phospho-AKT
(Ser473) by more than 30%, but it did not alter total
AKT expression.
Silencing of Plexin-B1 did not affect the proliferation of
SKOV3 cells
Increased AKT activity is associated with cell growth.
To determine whether the Plexin-B1 siRNA-induced
reduction of phospho-AKT (Ser473) would affect the
proliferation of SKOV3 cells, the MTT assay was used
to monitor the proliferation of untransfected SKOV3
cells and SKOV3 cells treated with Plexin-B1 siRNA2,
Plexin-B1 siRNA3 or negative control siRNA. As
showed in Figure 2C, there were no significant differ-
ences between the siRNA-treated groups and the
untreated group (P > 0.05).
Silencing of Plexin-B1 inhibited migration and invasion in
SKOV3 cells
Cancer cell migration and invasion are directly related
to metastasis. Plexin-B1 has been implicated in the pro-
cesses of cell mobility and cancer metastasis [37,38]. To
Table 1 Expression of Plexin-B1 in ovarian tissues of different pathological changes and its correlation with clinical
characteristics
Plexin-B1 expression
N = 120 Cases Positive Negative Positive Percentage (%) P
Normal & Benign 20 3 17 15.00 <0.001*
n.s.**
Borderline 20 7 13 35.00 n.s.*
Carcinoma 80 44 36 55.00
Nodal status
Positive 28 21 7 75.00 0.008
Negative 52 23 29 44.23
Tumour stage
I 20 9 11 45.00 n.s.
II 20 10 10 50.00
III 20 11 9 55.00
IV 20 14 6 70.00
Age(y)
<40 32 18 14 56.25 n.s.
≥40 48 26 22 54.17
Cell differentiation
High 32 14 18 43.75 n.s.
Medium 30 18 12 60.00
Low 18 12 6 66.67
<0.001* and n.s.** indicated differences of Plexin-B1 expression in normal ovaries and serous ovarian cystadenomas compared with that in serous borderline
ovarian tumours and serous ovarian cystadenocarcinomas respectively.
n.s.* indicated difference of Plexin-B1 expression in serous borderline ovarian tumours compared with that in serous ovarian cystadenocarcinomas.
n.s. indicated differences without statistical significance.
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inhibits SKOV3 cell migration and invasion, a wound-
healing assay and a cell invasion assay were performed
on SKOV3 cells either untransfected or transfected with
Plexin-B1 siRNA2, Plexin-B1 siRNA3 or negative
control siRNA for 24 h. As shown in Figure 3A-B, at 24
h and 48 h (respectively), Plexin-B1 siRNA2-treated
cells showed 40% and 70% wound closure, Plexin-B1
siRNA3-treated cells showed 40% and 60% wound clo-
sure, and negative control siRNA-treated cells showed
Figure 1 Expression of Plexin-B1 in benign, borderline, and malignant ovarian tissues and in ovarian cancer cell lines.
Immunohistochemical staining showed the presence of Plexin-B1 in human ovarian tissues with different pathological changes. In normal
ovaries (A) and benign serous ovarian cystadenomas (B), Plexin-B1 protein expression was virtually negative, whereas in serous borderline ovarian
tumors, Plexin-B1 expression was higher and stained membranes; the insert shows the dashed line region at a higher magnification to
demonstrate the membrane reaction product (C). In serous ovarian cystadenocarcinomas, Plexin-B1 expression was further up-regulated and
showed strong cytoplasmic staining (D). Representative images are shown. Magnification, ×200. Expression of Plexin-B1 in four human ovarian
cancer cell lines at both the mRNA and protein levels was detected with RT-PCR and western blotting. (E) RT-PCR showed the relative level of
mRNA for Plexin-B1 in SKOV3, A2780, C13* and OV2008 cells. GAPDH was used for normalization. Product sizes: Plexin-B1, 150 bp; GAPDH, 240
bp. (F) Western blot showing Plexin-B1 protein expression in SKOV3, A2780, C13* and OV2008 cells. b-actin was used as a loading control.
Product sizes: Plexin-B1, about 200 KD; b-actin, 43 KD.
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decreased the migration of SKOV3 cells. As shown in
Figure 3D-F, the number of SKOV3 cells that passed
through the filter in the Plexin-B1 siRNA2- (100 ± 52)
and siRNA3- (42 ± 36) treated groups was remarkably
less than that in the untreated (825 ± 32) or treated
with negative control siRNA (848 ± 41) groups, which
shows that inhibition of Plexin-B1 expression sup-
pressed SKOV3 cell invasion in vitro.
Silencing of Plexin-B1 altered the cytoskeleton of
SKOV3 cells
A previous study proved that Plexin-B1 regulates the
actin cytoskeleton by activating Rho activity [22]. To
investigate how changes in Plexin-B1 expression affect
the reorganization of the cytoskeleton, rhodamine-phal-
loidin was used to label F-actin in SKOV3 cells 24 h
after a 5-h exposure to Plexin-B1 siRNA2 or siRNA3.
A ss h o w ni nF i g u r e4 ,S K O V 3c e l l si nt h et r a n s f e c t e d
groups shrank without F-actin polymerization or filopo-
dia formation, whereas cells in the blank and control
groups showed pointed filopodia or polygonal cell
shapes with pointed edges, in which brightly stained
longitudinal actin bundles were detected [39].
Discussion
Plexins are a family of transmembrane receptors that
mediate repulsive neural responses induced by sema-
phorins. Increasing evidence suggests that plexins have
functions in multiple types of tumors and multiple
developmental processes, such as cell adhesion, migra-
tion, and apoptosis. Plexin-B1, a high-affinity receptor for
Sema 4D, is widely expressed in tissues outside the ner-
vous system and regulates angiogenesis [37,40], oncogen-
esis [27], cell mobility [26,41], mouse ovary follicular
growth and hormonogenesis [4] by initiating different
signaling pathways via its cytoplasmic region, which
binds and activates various intracellular molecules. It has
been reported that both the expression and roles of
Plexin-B1 are closely associated with cellular types and
with intracellular signaling molecules such as the recep-
tor tyrosine kinases ErbB2 and MET [26]. However, the
biological effects of Plexin-B1 are poorly understood.
Valente et al. [30] recently assessed the potential value
of Plexin-B1 expression, either alone or in conjunction
with Met, as a marker of tumor progression by analyz-
ing their expression in a series of 50 malignant epithelial
tumors (35 breast and 15 ovary). Plexin-B1 expression
was found in 7/11 ovarian serous adenocarcinomas, and
6/15 ovarian adenocarcinomas expressed both Met and
Plexin-B1, which was predictive of an unfavorable out-
come. In the present study, immunohistochemical analy-
sis was used to investigate Plexin-B1 expression in
ovarian serous tumors in a larger series. Consistent with
data reported previously by Valente et al., our results
revealed that elevated expression of Plexin-B1 was asso-
ciated with increasing tumor malignancy. Plexin-B1
levels ranged from 15.00% in normal and benign ovarian
tissues through 35.00% in borderline tumors to 55.00%
in malignant ovarian tumors, suggesting that Plexin-B1
Figure 2 Effects of Plexin-B1 siRNA on SKOV3 cells. (A) Real-time PCR was performed to detect Plexin-B1 mRNA levels in non-transfected
cells (Blank control) and cells at 24 h after a 5 h exposure to negative control siRNA or one of the three different Plexin-B1 siRNAs (Plexin-B1
siRNA1-3). The mean relative level ± SD of each group is shown. Plexin-B1 mRNA levels in three Plexin-B1 siRNA groups were significantly down-
regulated (*P < 0.01), while the negative control siRNA did not cause an obvious change. The bar graph shows the results of three independent
experiments. (B) Western blot analysis of lysates from untransfected (Blank control) SKOV3 cells and SKOV3 cells at 24 h after a 5-h exposure to
one of the three different Plexin-B1 siRNAs (Plexin-B1 siRNA1-3) or to negative control siRNA. The cells were analyzed by immunoblotting with
specific antibodies to Plexin-B1, p-AKT (s473), AKT and b-actin. Plexin-B1 expression was significantly down-regulated in each of the three Plexin-
B1 siRNA groups relative to the blank control group or the negative control group. p-AKT (s473) expression sequentially decreased in the three
Plexin-B1 siRNA groups, and AKT changed impalpably at the protein level. b-actin was the internal loading control. (C) The western blots were
scanned and quantified. Data present densitometric analyses of Plexin-B1, p-AKT (s473) or AKT relative to b-actin for n = 5 independent
experiments. * indicates P < 0.01 when compared to the blank control.
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Page 7 of 11might be an early factor in ovarian serous tumor devel-
opment. Furthermore, the tumors with lymph node
metastasis expressed higher levels of Plexin-B1 than
those without lymph node metastasis. Indeed, Plexin-B1
expression in precursor lesions suggested a certain role
of this protein in early ovarian carcinogenesis before
invasion or metastasis. It has been reported that Sema
4D might exert its proangiogenic effect via Plexin-B1 to
promote tumor growth and survival and thereby
facilitate tumor metastasis in head and neck squamous
cell carcinomas and other epithelial-derived tumors [37].
However, Plexin-B1 protein may have additional roles in
different types of tumors. For example, Plexin-B1 is
absent in more than 80% of renal cell carcinomas but
present in all kinds of renal tubules [28]. A possible
mechanism underlying this expression status is that the
Plexin-B1 gene is located in 3p21, which is a frequently
deleted region in renal cell carcinomas.
Figure 3 Effect of Plexin-B1 inhibition on SKOV3 cell proliferation, migration and invasion in vitro. (A) Cell migration capability was
determined with a wound healing assay. A confluent monolayer of untransfected SKOV3 cells or SKOV3 cells at 24 h after a 5-h exposure to
Plexin-B1 siRNA2, Plexin-B1 siRNA3 or negative control siRNA (Blank control) was wounded. Photographs were taken immediately (0 h) and at 24
h and 48 h after wounding. (B) Quantification of wound closure. The data present the mean distance of cell migration to the wound area at 24
h and 48 h after wounding in three independent wound sites per group. Values are means ± SD from at least three independent experiments.
(C) Analysis of the proliferation of untransfected (Blank control) SKOV3 cells and SKOV3 cells 72 h after treatment with Plexin-B1 siRNA2, Plexin-B1
siRNA3 or negative control siRNA. The data present the mean proliferation rate ± SD from three independent assays. (D) Cell invasion capability
was assessed with a transwell assay. Untransfected (Blank control) SKOV3 cells and SKOV3 cells at 24 h after a 5-h exposure to Plexin-B1 siRNA2,
Plexin-B1 siRNA3 or negative control siRNA were trypsinized and then plated in the upper chamber and allowed to grow for 48 h in serum-free
medium. Cells that invaded the underside of the filter were fixed and stained. (D) Quantification of the transwell assay. The data present the
mean number of cells on the bottom surface of the membrane from independent assays performed in triplicate. There were fewer invaded cells
in the Plexin-B1 siRNA2 group (100 ± 52) and the siRNA3 group (42 ± 36) than in the blank control group (825 ± 32) or the negative control
siRNA group (848 ± 41). * indicates P < 0.01 when compared to the blank control.
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response to Sema 4D, Plexin-B1 stimulates endothelial
cell migration by activating the PI3K/AKT signaling
pathway [3,41]. The present work showed that reducing
Plexin-B1 expression in SKOV3 cells inhibited AKT
activity by reducing the level of phospho-AKT (Ser473),
which plays important roles in regulating cell prolifera-
tion, migration and invasion. However, the proliferation
rate of SKOV3 cells was not affected by Plexin-B1
knock-down, suggesting that Plexin-B1 has no essential
role in regulating the proliferation of SKOV3 cells.
Swiercz et al. [26] demonstrated that Plexin-B1 activates
the the PI-3-kinase/Akt pathway in response to Sema
4D, but requires ErbB-2 to activate RhoA and conse-
quently promote cell migration. Interestingly, they also
suggested that Plexin-B1 inhibits RhoA activity in the
presence of Met, resulting in an antimigratory effect.
They proposed a novel mechanism by which Plexin-B1-
mediated signaling can be regulated via differential asso-
ciation with ErbB-2 and Met, and the cellular effects
elicited by Plexin-B1 are hypothesized to be determined
by the relative expression levels of ErbB-2 and Met,
which compete to mediate Sema 4D’s effects. In our
study, the SKOV3 cells expressed both Met and ErbB-2
[42,43], and inhibition of Plexin-B1 resulted in reduc-
tions in cell motility and invasive capacity. These results
indicate that Plexin-B1 may principally interact with
ErbB-2 to activate AKT in SKOV3 cells and conse-
quently stimulate the PI3K/AKT pathway, which plays a
key role in the progression and metastasis of various
human ovarian cancers [35].
To date, Plexin-B1 has been shown to induce the reor-
ganization of the cytoskeleton by stimulating different
downstream adaptors. On the one hand, dimerization of
Plexin-B1 is sufficient to induce ErbB2-dependent
activation of Rho and to regulate the remodeling of the
actin cytoskeleton and alter cell movement in response
to Sema 4D [22]. On the other hand, it has been shown
that Plexin-B1 inactivates PI3K, dephosphorylates AKT
and activates GSK-3b through R-Ras GAP activity. Acti-
vation of GSK-3b leads to inhibition of microtubule poly-
merization and stabilization [44]. In this study, we found
that effective suppression of Plexin-B1 in SKOV3 cells
led to cell shrinkage and loss of polarity without F-actin
polymerization or filopodia formation. The loss of cell
polarity in terms of actin assembly and stable microtu-
bule distribution suggested that there should also be
defects in cell migration and invasion [45]. Furthermore,
several other regulators of the actin cytoskeleton may
also be implicated in the Plexin-B1-induced reorganiza-
tion of SKOV3 cells. For example, the MEK/ERK signal-
ing pathway, which was reported to be constitutively
activated in epithelial ovarian cancer cells [46], has been
shown to restore stress fibers in transformed fibroblasts
[47], and a recent study suggested that Plexin-B1 can uti-
lize RhoA to stimulate ERK [48].
However, in this report, it remains uncertain whether
the reduced AKT activity induced by Plexin-B1 inhibi-
tion and the corresponding cellular responses are the
result of Sema 4D produced by SKOV3 cells acting on
the Plexin-B1 receptor to stimulate downstream mole-
cules via an autocrine/paracrine mechanism, or whether
overexpression and consequent clustering of Plexin-B1
in SKOV3 cells leads to phosphorylation of its cytoplas-
mic region. We have produced a Sema 4D fusion pro-
tein in vitro and further investigations are under way. In
addition, studies addressing whether this oncogenic
function of Plexin-B1 in SKOV3 cells is a cell type-spe-
cific effect or instead is shared across multiple ovarian
cancer cell lines are ongoing.
Figure 4 Effect of Plexin-B1 inhibition on cytoskeleton rearrangement. Representative cytoskeletal rearrangements (phalloidin-fluorescein
isothiocyanate staining) of untransfected (Blank control) SKOV3 cells and SKOV3 cells at 24 h after a 5-h exposure to Plexin-B1 siRNA2, Plexin-B1
siRNA3 or negative control siRNA. Repression of Plexin-B1 by Plexin-B1 siRNA2 and siRNA3 inhibited F-actin polymerization and filopodia
formation in SKOV3 cells. Red indicates F-actin.
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Page 9 of 11Conclusions
Plexin-B1 was strongly expressed in tissues of patients
with ovarian serous adenocarcinomas and its expression
was found to be associated with lymph node metastasis.
In vitro assays indicated that Plexin-B1 contributes to
tumor migration and invasion. Additional studies are
warranted to elucidate the role of Plexin-B1 as a possi-
ble tumor marker as well as a putative therapeutic target
for ovarian serous tumors.
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